Table_1_Daily Intake of a Phaseolus vulgaris L. Snack Bar Attenuates Hypertriglyceridemia and Improves Lipid Metabolism-Associated Plasma Proteins in Mexican Women: A Randomized Clinical Trial.DOCX

Current efforts to prevent dyslipidemia are focused on the development of functional products as an alternative for hypertriglyceridemia management. This study assessed the metabolic effect of the daily consumption of a bean and oats snack bar (BOSB) on hypertriglyceridemia biomarkers among Mexican women. An 8-weeks randomized parallel clinical trial (ID: NCT0496694, https://clinicaltrials.gov/ct2/show/NCT04966494) was conducted with 26 hypertriglyceridemic women allocated to BOSB group (TG = 208.18 ± 56.97 mg/dL) and control group (TG = 182.28 ± 51.39 mg/dL). Only the BOSB group consumed 50 g of the product per day. Fasting blood samples were taken from women with an adherence ≥ 90%. A targeted proteomic analysis with plasma samples of control and BOSB groups were conducted using a human obesity antibody array kit and bioinformatic tools provided by the Ingenuity Pathways Analysis (IPA) software. Serum TG levels in the BOSB group decreased by 37.80% (132.04 ± 27.83 mg/dL) compared with the control group (178.87 ± 32.01 mg/dL); glucose levels decreased by 5.69% in the BOSB group (87.55 ± 3.36 mg/dL). A modest body weight (5%) reduction was also found. Forty proteins were differentially modulated by the BOSB consumption (fold change > 1.2). The proteomic analysis revealed the involvement of BOSB bioactives in prevention of monocytes recruitment and localized inflammatory response, inhibition of pre-adipocyte maturation and adipogenesis, inhibition of hepatic b-oxidation, and potential satiety regulation. These results are promising since the mere intervention with the BOSB reduced serum TG without diet restriction, giving insights for further research in prevention of hypertriglyceridemia.

当前预防血脂异常的努力集中于开发功能性产品，作为高甘油三酯血症管理的替代方案。本研究评估了每日摄入豆类和燕麦棒（BOSB）对墨西哥女性高甘油三酯血症生物标志物的代谢效应。一项为期8周的随机平行临床试验（ID：NCT0496694，https://clinicaltrials.gov/ct2/show/NCT04966494）对26名高甘油三酯血症女性进行了分组，分为BOSB组（甘油三酯水平为208.18 ± 56.97 mg/dL）和对照组（甘油三酯水平为182.28 ± 51.39 mg/dL）。仅BOSB组每日摄入50克该产品。对依从性≥90%的女性进行空腹血液样本采集。使用人肥胖抗体阵列试剂盒和由Ingenuity Pathways Analysis（IPA）软件提供的生物信息学工具对对照组和BOSB组的血浆样本进行了靶向蛋白质组学分析。与对照组（178.87 ± 32.01 mg/dL）相比，BOSB组的血清甘油三酯水平下降了37.80%（132.04 ± 27.83 mg/dL）；BOSB组的血糖水平下降了5.69%（87.55 ± 3.36 mg/dL）。还观察到体重的适度减少（5%）。BOSB的摄入导致40种蛋白质差异调节（变化倍数>1.2）。蛋白质组学分析揭示了BOSB生物活性在预防单核细胞募集和局部炎症反应、抑制前脂肪细胞成熟和脂肪生成、抑制肝脏β-氧化以及潜在饱腹感调节中的作用。这些结果颇具希望，因为仅通过BOSB的干预就降低了血清甘油三酯水平，而无需限制饮食，为高甘油三酯血症的预防研究提供了新的启示。